Canada does not treat sun protection as cosmetics. The moment a product claims to protect skin from ultraviolet radiation, it leaves the Cosmetic Regulations and lands in one of two other systems — and which one it lands in is decided by the UV filters in the formula.
Brands exporting from Korea routinely get this backwards. They assume the cosmetic notification that carried them into other markets will carry them into Canada, then discover the product cannot legally be sold under that framework at all.
Two doors, and the filter chooses which one
A sun protection product whose active ingredients are zinc oxide, titanium dioxide, or both is regulated in Canada as a Natural Health Product. It requires a product licence and is issued a Natural Product Number, the NPN that appears on the pack.
A product containing synthetic organic UV filters — the avobenzone and octocrylene family — is regulated as a drug and requires a Drug Identification Number instead.
That distinction is the whole reason mineral sunscreen matters commercially in this market. The NHP pathway exists for it, the application is assessed against a different set of expectations than a drug submission, and the resulting number on the carton is different. Brands that have built a formula on a mixed filter system, which is common in Korean sun care, should know before they file that a single organic filter moves the entire product to the drug side.
When cosmetic classification does apply
There is a narrow case. A product that contains no sun protection claim anywhere — not on the pack, not on the website, not in the retailer’s product description — can remain a cosmetic even if the formula happens to contain a UV-attenuating pigment. Titanium dioxide used purely as a colourant sits here.
The trap is that the claim, not the intention, decides. Marketing copy written by a distributor, or an SPF figure a retailer adds to a listing, can reclassify a product the brand filed as a cosmetic. This is worth writing into distributor agreements rather than trusting to goodwill.
The monograph sets the ceiling on what you can say
Health Canada maintains a sunscreen monograph that specifies which actives are permitted, at what concentrations, which claims may be made, and what label text is mandatory. Filing against the monograph is the fast route; a product that stays inside it faces a far more predictable review than one that asks for something outside it.
Practically, this means claim language is not a creative decision. Terms like broad spectrum and water resistant have defined meanings and defined evidence behind them. A phrase invented in a brand deck will not survive review, and rewriting the pack after artwork is finalised is expensive in a way that reviewing the monograph first is not.
It also means claims that stray beyond sun protection deserve scrutiny. Positioning a sunscreen around blue light or pollution may be interesting in other markets, but each additional claim needs its own justification and can complicate an otherwise straightforward filing.
Testing you have to budget for
SPF is determined by in vivo testing on human panels under ISO 24444. It is not calculated from the concentration of filters, and it cannot be inherited from a similar formula. Any change to the base — a different emollient system, a new dispersion of the same pigment, a reformulated preservative — can alter the film the product forms on skin, and the film is what produces the SPF.
Broad spectrum performance requires separate UVA testing, and water resistance requires its own protocol on top of that. Each is a distinct study with its own cost and lead time, and lead times at accredited laboratories are the constraint that most often pushes a launch date.
The sourcing consequence is straightforward: lock the formula before you test, and understand that a cost-down exercise on raw materials after testing may require the whole panel study again. Manufacturers see this repeatedly — a brand approves a formula, tests it, then asks to substitute an ingredient to hit a margin target, and discovers the substitution has invalidated the number on the pack.
Bilingual labelling changes the pack, not just the copy
Canadian labelling obligations require English and French. For a small tube or a compact stick, that is a physical design problem before it is a translation problem — the mandatory text roughly doubles while the available surface stays the same.
Brands discover this late and solve it badly, usually by shrinking type to the edge of legibility or adding a peel-back label that ruins the pack aesthetic. Designing for both languages from the first artwork round costs nothing. Retrofitting them costs a print run.
The same discipline applies to the directions for use and warning statements, which are not optional and not summarisable. They occupy space, and that space has to be allocated at concept stage.
White cast, particle size, and the reformulation trap
The persistent formulation complaint about zinc and titanium sunscreens is the white cast, and the persistent fix is smaller particles and surface treatments such as silica coating that improve dispersion and cosmetic feel.
Reducing particle size solves the aesthetic and creates a regulatory conversation. Nanoscale materials attract specific scrutiny and disclosure expectations that vary by jurisdiction, so a brand selling the same formula in several regions may face different labelling obligations for identical material. Grade and particle size distribution should be documented from the supplier, not assumed.
Surface treatment also affects how the dispersion behaves in the base, which loops back to the testing point above. A change of pigment grade is a formulation change, and formulation changes have consequences for the SPF file even when the percentage on the spec sheet stays the same.
This is where Korean manufacturing has a genuine advantage worth using in a pitch. The sensory work that produced the light, non-chalky textures now common in the region’s sun care formulations is exactly what the North American market has been slow to deliver in a filter system it already accepts.
Sequence the work correctly
The pattern that works is unglamorous. Confirm the filter system and therefore the regulatory pathway before development begins. Check the intended claims against the monograph before writing any marketing. Lock the formula, then test. Design the pack bilingually from the start. Keep the licence holder and the distributor’s marketing on the same page in writing.
Done in that order, a Canadian launch is a scheduling exercise. Done in reverse — which is how most brands arrive, formula finished and artwork approved — it becomes a reformulation, a re-test, and a missed season. Brands that have already navigated a demanding regime elsewhere, such as the registration process in Gulf markets, tend to handle this better, because they have learned to treat classification as the first design input rather than the last administrative step.
“Classification questions like this come up constantly with brands looking to expand into North America — whether a sun care product is handled as a drug or as a natural health product changes the entire go-to-market timeline and cost structure. What we tell clients is to treat classification as a strategic decision made early, not a compliance afterthought bolted on right before launch. The brands that map out a target market’s system during formulation, rather than after, consistently get to shelf faster and avoid costly reformulation down the line.” — Hyejin Cho, Digital Marketing Specialist, Marketing and Communication Team at SPSCOS